Sales of the cancer treatment Darzalex helped Johnson & Johnson deliver better-than-expected third-quarter earnings, while COVID-19 fueled vaccine revenue and had more customers reaching for Tylenol. The world’s biggest maker of health care products hiked its 2021 earnings forecast after saying Tuesday that net income climbed 3% to $3.67 billion in the recently completed quarter. Sales of the company’s single-shot COVID-19 vaccine started to pick up in the quarter and nearly doubled what it brought in during the first half of 2021. J&J also said that sales of over-the-counter drugs, which do not need prescriptions, grew 18% globally as more customers bought Tylenol and Motrin partly because they wanted vaccine symptom relief. [time-brightcove not-tgx=”true”] Injections of COVID-19 vaccines, which have been widely available since spring, can come with side effects like arm soreness or a temporary fever. J&J rang up $502 million in sales from its COVID-19 vaccine in the third quarter after pulling in $264 million during the first half of 2021. The New Brunswick, New Jersey, company’s vaccine started slow earlier this year.